Disha Vadgama
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Disha Vadgama has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Joachim G. J. V. Aerts
Department of Respiratory Medicine, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands
25 shared publications - Anne Onrust-Van Schoonhoven
Erasmus University Medical Center 1 Department of Pulmonary Medicine Rotterdam, the Netherlands
14 shared publications - Arjen Joosse
Erasmus MC Cancer Institute 2 , Erasmus University Medical Center, Rotterdam, the Netherlands
14 shared publications - Astrid A. M. van der Veldt
Department of Medical Oncology, Erasmus University Medical Center, Rotterdam, the Netherlands; Department of Radiology & Nuclear Medicine, Erasmus University Medical Center, Rotterdam, the Netherlands
14 shared publications - Christianne Groeneveldt
Erasmus University Medical Center 1 Department of Pulmonary Medicine Rotterdam, the Netherlands
14 shared publications - Daphne W. Dumoulin
Department of Pulmonary Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands
14 shared publications
Latest Publications
- Open Access
- 12 November 2026
- Published by Elsevier in Lung Cancer
Decoding immune signatures driving brain metastases in stage III non-small cell lung cancer
- 12 November 2026
- Published by Elsevier in Lung Cancer
Open AccessDecoding immune signatures driving brain metastases in stage III non-small cell lung cancer
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Data from Neutralizing the IL12/IL23 p40 Subunit Prevents Immune Checkpoint Blockade Toxicity without Compromising Antitumor Efficacy
Immune checkpoint blockade (ICB) has markedly improved overall survival in various cancers but is associated with severe and sometimes fatal immune-related adverse events (irAE). Current management of irAEs involves discontinuation of ICB therapy and administration of immunosuppressive drugs, such as corticosteroids, which have been associated with decreased antitumor efficacy. Although irAE development is associated with ICB response, it is currently unknown whether their underlying mechanisms are shared or distinct. To identify early and targetable drivers of irAEs, we performed proteomic analyses on the serum of patients with cancer treated with anti–programmed cell death protein 1 (PD-1) and anti–cytotoxic T lymphocyte–associated protein 4 (CTLA-4) combination ICB. We identified a significantly increased concentration of p40, a subunit of interleukin (IL) 12/IL23, shortly after the start of ICB but before the onset of clinically apparent irAEs. Importantly, increased p40 levels were not associated with ICB efficacy. Neutralizing p40 mitigated ICB-induced toxicity in various mouse models without impairing ICB-induced antitumor efficacy. In conclusion, we demonstrated that IL12/IL23p40 is a key mediator of ICB-induced toxicity while being redundant for ICB antitumor efficacy. This shows that the mechanisms underlying ICB toxicity and efficacy can be uncoupled and provides a rationale for p40 blockade in clinical trials with ICB treatment to prevent irAEs in patients.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Neutralizing the IL12/IL23 p40 Subunit Prevents Immune Checkpoint Blockade Toxicity without Compromising Antitumor Efficacy
Immune checkpoint blockade (ICB) has markedly improved overall survival in various cancers but is associated with severe and sometimes fatal immune-related adverse events (irAE). Current management of irAEs involves discontinuation of ICB therapy and administration of immunosuppressive drugs, such as corticosteroids, which have been associated with decreased antitumor efficacy. Although irAE development is associated with ICB response, it is currently unknown whether their underlying mechanisms are shared or distinct. To identify early and targetable drivers of irAEs, we performed proteomic analyses on the serum of patients with cancer treated with anti–programmed cell death protein 1 (PD-1) and anti–cytotoxic T lymphocyte–associated protein 4 (CTLA-4) combination ICB. We identified a significantly increased concentration of p40, a subunit of interleukin (IL) 12/IL23, shortly after the start of ICB but before the onset of clinically apparent irAEs. Importantly, increased p40 levels were not associated with ICB efficacy. Neutralizing p40 mitigated ICB-induced toxicity in various mouse models without impairing ICB-induced antitumor efficacy. In conclusion, we demonstrated that IL12/IL23p40 is a key mediator of ICB-induced toxicity while being redundant for ICB antitumor efficacy. This shows that the mechanisms underlying ICB toxicity and efficacy can be uncoupled and provides a rationale for p40 blockade in clinical trials with ICB treatment to prevent irAEs in patients.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Neutralizing the IL12/IL23 p40 Subunit Prevents Immune Checkpoint Blockade Toxicity without Compromising Antitumor Efficacy
Figure S1. Gating strategy for flow cytometric analysis of the T-cell compartment.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Neutralizing the IL12/IL23 p40 Subunit Prevents Immune Checkpoint Blockade Toxicity without Compromising Antitumor Efficacy
Figure S1. Gating strategy for flow cytometric analysis of the T-cell compartment.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Figure S10 from Neutralizing the IL12/IL23 p40 Subunit Prevents Immune Checkpoint Blockade Toxicity without Compromising Antitumor Efficacy
Figure S10. p40 neutralization during ICB therapy with CTLA-4 clone 9D9.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S10 from Neutralizing the IL12/IL23 p40 Subunit Prevents Immune Checkpoint Blockade Toxicity without Compromising Antitumor Efficacy
Figure S10. p40 neutralization during ICB therapy with CTLA-4 clone 9D9.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Figure S11 from Neutralizing the IL12/IL23 p40 Subunit Prevents Immune Checkpoint Blockade Toxicity without Compromising Antitumor Efficacy
Figure S11. Outgrowth of subcutaneous MC38 tumors after ICB mono- or combination therapy.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S11 from Neutralizing the IL12/IL23 p40 Subunit Prevents Immune Checkpoint Blockade Toxicity without Compromising Antitumor Efficacy
Figure S11. Outgrowth of subcutaneous MC38 tumors after ICB mono- or combination therapy.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Neutralizing the IL12/IL23 p40 Subunit Prevents Immune Checkpoint Blockade Toxicity without Compromising Antitumor Efficacy
Figure S2. Baseline gene signatures and corresponding pathways associated with development of irAEs.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Neutralizing the IL12/IL23 p40 Subunit Prevents Immune Checkpoint Blockade Toxicity without Compromising Antitumor Efficacy
Figure S2. Baseline gene signatures and corresponding pathways associated with development of irAEs.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Neutralizing the IL12/IL23 p40 Subunit Prevents Immune Checkpoint Blockade Toxicity without Compromising Antitumor Efficacy
Figure S3. Week 3 gene signatures and corresponding pathways associated with development of irAEs and therapeutic response following ICB.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Neutralizing the IL12/IL23 p40 Subunit Prevents Immune Checkpoint Blockade Toxicity without Compromising Antitumor Efficacy
Figure S3. Week 3 gene signatures and corresponding pathways associated with development of irAEs and therapeutic response following ICB.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Neutralizing the IL12/IL23 p40 Subunit Prevents Immune Checkpoint Blockade Toxicity without Compromising Antitumor Efficacy
Figure S5. IL-12/IL-23p40 accumulates in serum, regardless of the type of toxicity or cancer.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Neutralizing the IL12/IL23 p40 Subunit Prevents Immune Checkpoint Blockade Toxicity without Compromising Antitumor Efficacy
Figure S5. IL-12/IL-23p40 accumulates in serum, regardless of the type of toxicity or cancer.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from Neutralizing the IL12/IL23 p40 Subunit Prevents Immune Checkpoint Blockade Toxicity without Compromising Antitumor Efficacy
Figure S7. p35 neutralization mitigates ICB-induced toxicity.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Neutralizing the IL12/IL23 p40 Subunit Prevents Immune Checkpoint Blockade Toxicity without Compromising Antitumor Efficacy
Figure S7. p35 neutralization mitigates ICB-induced toxicity.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Neutralizing the IL12/IL23 p40 Subunit Prevents Immune Checkpoint Blockade Toxicity without Compromising Antitumor Efficacy
Figure S4. Cytokines driving CD4+ T-cell responses in colonic biopsies after ICB therapy.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Neutralizing the IL12/IL23 p40 Subunit Prevents Immune Checkpoint Blockade Toxicity without Compromising Antitumor Efficacy
Figure S4. Cytokines driving CD4+ T-cell responses in colonic biopsies after ICB therapy.